Mass Spectrometry-based Protein Biomarker Analysis in Chemoimmunotherapy Combinations Identifies Unique Immune Signatures in Pancreatic Cancer - Biognosys

Mass Spectrometry-based Protein Biomarker Analysis in Chemoimmunotherapy Combinations Identifies Unique Immune Signatures in Pancreatic Cancer

Poster presented at SITC 2022

Presenter: Nigel Beaton
In collaboration with the Parker Institute for Cancer Immunotherapy (PICI)

Back to Resources overview

Helpdesk

Access our knowledge base with relevant resources and guiding information.

Contact

    Close banner

    New: Spectronaut® 17

    A Groundbreaking Increase in Identifications

    New: Spectronaut® 17

    A Groundbreaking Increase in Identifications

    Learn More